Dr. Holstein on BiTEs in Multiple Myeloma

Sarah Holstein, MD, PhD
Published: Tuesday, Mar 19, 2019



Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.

There is much excitement surrounding AMG 420, which is the first BiTE candidate in multiple myeloma, says Holstein. In a phase I study evaluating AMG 420, 7 of 10 patients with heavily pretreated multiple myeloma who were administered a 400-µg/day dose responded to the therapy; 4 patients achieved a complete response (CR). Moreover, the 4 patients with CRs and 1 patient who achieved a partial response had no minimal residual disease. The BiTE candidate binds to the antigen BCMA that is expressed on multiple myeloma cells, which makes it a viable candidate worth pursuing in the space.

The idea behind these engagers is to take the antigen recognition part of an antibody that identifies BCMA on the surface of myeloma cells and an antibody recognizing CD3 on a T cell. Through this recognition, the 2 antibodies hook together, which allows the T cell to be brought to the myeloma cell. As a result, cytotoxic T cells are brought directly to the target cancer cell, explains Holstein.
SELECTED
LANGUAGE


Sarah Holstein, MD, PhD, associate professor of medicine, University of Nebraska Medical Center, discusses the emergence of bispecific T-cell engagers (BiTEs) in multiple myeloma.

There is much excitement surrounding AMG 420, which is the first BiTE candidate in multiple myeloma, says Holstein. In a phase I study evaluating AMG 420, 7 of 10 patients with heavily pretreated multiple myeloma who were administered a 400-µg/day dose responded to the therapy; 4 patients achieved a complete response (CR). Moreover, the 4 patients with CRs and 1 patient who achieved a partial response had no minimal residual disease. The BiTE candidate binds to the antigen BCMA that is expressed on multiple myeloma cells, which makes it a viable candidate worth pursuing in the space.

The idea behind these engagers is to take the antigen recognition part of an antibody that identifies BCMA on the surface of myeloma cells and an antibody recognizing CD3 on a T cell. Through this recognition, the 2 antibodies hook together, which allows the T cell to be brought to the myeloma cell. As a result, cytotoxic T cells are brought directly to the target cancer cell, explains Holstein.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x